Virtuix (VTIX) Director Read Randolph Receives RSU Award

What Happened

• Read Randolph C., a director of Virtuix Holdings, was granted 189,075 restricted stock units (RSUs) on September 24, 2026 under the company's 2025 Omnibus Incentive Plan. The RSUs were granted at $0.00 (no cash paid) and represent a contingent right to one share of Class A common stock each.
• On the same date, the vesting of 45,000 previously granted RSUs (originally granted Oct 9, 2025) was accelerated in full and the shares underlying those RSUs were issued to Mr. Randolph.

Key Details

• Transaction date: September 24, 2026. Form 4 filed: September 28, 2026 (reporting period: Sep 24, 2026). Note: Form 4s are generally due within two business days of the transaction; this filing was four days after the transaction date and appears to be late.
• Grant price / cash paid: $0.00; reported acquisition value $0 (these are equity awards, not a cash purchase).
• Vesting for the 189,075 RSUs: they vest in full on the earlier of (i) the Company’s 2027 annual meeting of stockholders or (ii) October 24, 2027 (13 months after the Sep 24, 2026 vesting start date), subject to continued service.
• Shares/ownership after transaction: 45,000 shares of Class A common stock were issued (from accelerated RSUs) plus 189,075 unvested RSUs remain outstanding for Mr. Randolph (as reported in the filing).
• Plan / footnotes: Grants issued under the 2025 Omnibus Incentive Plan. Footnotes describe the RSU terms and the acceleration/issuance of the prior 45,000 RSUs.

Context

• RSUs are a form of equity compensation that convert to shares on vesting; they are not an open-market purchase (so they don’t directly signal buying intent) nor a sale.
• Acceleration and issuance of previously granted RSUs means those earlier awards became immediate share ownership rather than remaining contingent.
• For retail investors, award grants increase potential future share count (dilution when RSUs vest) and indicate director compensation, but do not necessarily reflect the director’s view on the company’s near-term stock prospects.